AzTrials
AzTrials

Gynecologic DiseaseNCT02450084

Ultrasound-guided Bilateral Rectus Sheath Block for Robotic Single-port Gynecologic Surgery

A study testing Rectus sheath block, Ropivacaine and Bandage in people with Gynecologic Disease, run by Ewha Womans University Mokdong Hospital at 1 site in South Korea.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Rectus sheath block (RSB) is a kind of anterior abdominal wall block. It has postoperative analgesic effect for abdominal surgery with midline incision. Robotic gynecologic surgery is accompanied by significant postoperative pain and usually IV-PCA is used to manage the pain.The purpose of this study is to investigate… Read more about this study

Who is it for?
Ages 21 to 60 years, women only
Conditions the study is for
Gynecologic Disease
What is being tested?
Rectus sheath block, Ropivacaine and Bandage
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteSouth Korea
Study dates
May 2015to 31 Jan 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 60 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Robotic single-port gynecologic surgery
  • American society of Anesthesiologists (ASA) physical status classification I-II
  • Age: 21-60

Who cannot join

  • Gynecologic cancer operation
  • History of previous abdominal surgery
  • Allergy to local anesthetics(ropivacaine)
  • Opioid tolerance
  • Coagulopathy
  • Infection at the needle insertion site
  • Difficulty to cooperating

Trial locations and contacts

1 site in 1 country.

South Korea1 site
  • Ewha Womans University Mokdong Hospital

    Seoul, 158-710

Other trials in South Korea

About this study

Official title: Postoperative Analgesic Effects of Ultrasound-guided Bilateral Rectus Sheath Block for Robotic Single-port Gynecologic Surgery

Rectus sheath block (RSB) is a kind of anterior abdominal wall block. It has postoperative analgesic effect for abdominal surgery with midline incision. Robotic gynecologic surgery is accompanied by significant postoperative pain and usually IV-PCA is used to manage the pain.The purpose of this study is to investigate the analgesic effect of ultrasound-guided RSB to single-port robotic gynecologic surgery which has incision site at umbilical area. Patients will randomly assigned to two groups, RSB group and Control group. Each patients will assessed for time to first rescue analgesia, verbal numerical rating pain scores, number of rescue analgesic demands, and postoperatively opioids use by IV-PCA by a blinded investigator at 0, 1, 6, 12, 24 and 48 hours postoperatively.

Read the detailed description

Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. The procedure will be performed bilaterally and 15 ml on each side, total 30 ml of 0.25% ropivacaine will be injected. After the procedure, a surgery scheduled will be proceeded. Patient of Control group will be proceeded the surgery after induction of anesthesia. All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively. If a patient complains pain more intense than VNRS 4 or demands an analgesic drug, a rescue analgesic would be allowed.

Being tested
Rectus sheath block, Ropivacaine, Bandage, IV-PCA containing Fentanyl
Medical subject headings
Genital Diseases, Female

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Rectus sheath blockProcedure or surgery

    Also called RSB

    Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine

  • RopivacaineDrug

    Also called Naropin

    Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine

  • BandageOther

    After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.

  • IV-PCA containing FentanylDrug

    Also called Intravenous patient controlled analgesia using fentanyl

    All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.

Study groups in NCT02450084
Study groupRoleWhat they receive
Rectus sheath blockExperimentalPatients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl 800 µg for 48 hours postoperatively.
Receives: Procedure: Rectus sheath block; Drug: Ropivacaine; Other: Bandage; Drug: IV-PCA containing Fentanyl
ControlSham comparatorPatients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl 800µg for 48 hours postoperatively.
Receives: Other: Bandage; Drug: IV-PCA containing Fentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Verbal numerical rating scale

    Postoperative pain on each time point which is expressed by verbal numerical rating scale (0 ~ 10)

    Measured: 6 hours postoperatively

Secondary outcomes (3)
  1. Total opioids use

    Total dosage of injected fentanyl through IV-PCA

    Measured: 0, 1, 6, 12, 24, 48 hours postoperatively

  2. Time to first rescue analgesic request

    How long it takes postoperative time to first additional analgesic drug injection by patient's request

    Measured: 48 hours postoperatively

  3. Verbal numerical rating scale

    Postoperative pain on each time point which is expressed by verbal numerical rating scale (0 ~ 10)

    Measured: 0, 1, 12, 24, 48 hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 May 2015 (estimated)
  2. Study startMay 2015
  3. Primary completion31 Jan 2017
  4. Study completion31 Jan 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02450084
Sponsor's protocol ID
EUMC 2015-01-024-002
Status last verified
Feb 2017
First submitted
8 May 2015
Last updated
8 Feb 2017
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Rectus sheath block, Ropivacaine and Bandage in people with Gynecologic Disease, run by Ewha Womans University Mokdong Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Verbal numerical rating scale (time frame: 6 hours postoperatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in